In a randomised placebo‑controlled crossover study, MDMA (125 mg) significantly raised plasma copeptin—a stable surrogate for AVP—in women but not men, with a nonsignificant AVP rise and evidence of increased renal water retention. These effects were blocked by duloxetine, implicating MDMA‑induced serotonin and noradrenaline release in the sex‑specific AVP/copeptin response and offering a mechanism for the higher incidence of hyponatraemia in female ecstasy users.
- Published
- Journal
- Journal of Clinical Endocrinology Metabolism
- Authors
- Simmler, L. D., Hysek, C. M., Liechti, M. E.